CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 132 enrolled
Drug / intervention
Medroxyprogesterone 17-Acetate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01019369
NCT01019369N/ACompleted

Randomized Clinical Trial of Self Versus Clinical Administration of Depot Medroxyprogesterone Acetate

Carolyn L. Westhoff·interventional·Posted Nov 25, 2009·Updated May 7, 2019

In Brief

A clinical study evaluating Medroxyprogesterone 17-Acetate for Contraception. Completed, enrolled 132 participants across 1 site.

Detailed Summary

Depot medroxyprogesterone acetate (DepoProvera) is an acceptable form of contraception for many women. However, difficulty in access may cause many women to discontinue use, often without the use of another effective method of contraception, thereby leaving them vulnerable to unintended pregnancy. This study will randomly assign women who present for contraceptive services to two groups: self or clinic administered SC DMPA. The participants will be followed for one year to compare continuation rates, acceptability, cost effectiveness, evidence of skin changes, and need for continued support between the two groups.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsContraception
CountriesUnited States

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 25, 2009
Enrollment StartMar 1, 2010
Primary CompletionJan 1, 2011
Study CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 16.6 years ago

Interventions

Medroxyprogesterone 17-Acetatedrug

Depot medroxyprogesterone acetate, SC, every 12 weeks for 1 year

Medroxyprogesterone 17-Acetatedrug

Depot medroxyprogesterone acetate, SC, every 12 weeks for 1 year